Interim report Q2/2024: Enzymatica builds momentum for expansion

"Many factors now point to a favorable pathway for Enzymatica. We are making great strides in research, we have received the MDR certification, we are garnering international interest and we are seeing signs of regulatory developments that could be beneficial to us. At the same time, we need to expand our partner network, which does not happen overnight. Registrations in new countries will delay the launch in the largest international markets and we want to increase our research efforts. "Many...

"Many factors now point to a favorable pathway for Enzymatica. We are making great strides in research, we have received the MDR certification, we are garnering international interest and we are seeing signs of regulatory developments that could be beneficial to us. At the same time, we need to expand our partner network, which does not happen overnight. Registrations in new countries will delay the launch in the largest international markets and we want to increase our research efforts.

The board's decision to update the financial goals and acquire more capital for the company gives us the peace of mind and long-term perspective required to build momentum in the autumn together with existing and new partners and then achieve the strong sales growth that we have planned for several years. I am convinced that the world will see a strong and successful Enzymatica rise in the next few years", said Claus Egstrand, CEO.

Significant events during the quarter

Significant events after the quarter

Other events during and after the quarter

The full report is available on: www.enzymatica.com/investors/financial-reports

This information is information that Enzymatica is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out below, at 08:30 a.m. CET on July 18, 2024.

For more information, please contact:
Claus Egstrand, Chief Executive Officer, Enzymatica AB
Phone: +44 7780 22 8385 | Email: [email protected] 

This information was brought to you by Cision http://news.cision.com

https://news.cision.com/enzymatica-ab/r/interim-report-q2-2024-enzymatica-builds-momentum-for-expansion,c4016269

The following files are available for download:

 

View original content:https://www.prnewswire.co.uk/news-releases/interim-report-q22024-enzymatica-builds-momentum-for-expansion-302200408.html